A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
Recap by typeshit. Full story at Dr. Michael Moeller.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
8:32
Archibald follows up his earlier retatrutide video with a look at its uses. Retatrutide is still an investigational drug and is not FDA approved.
Bikman argues the facial change reflects rapid weight loss in general and suggests using the drug as a short-term aid for carb cravings. His view, not settled fact.
A shared research summary evaluating how GLP-1 receptor agonists affect deaths and hospital stays in people with type 2 diabetes. Details are thin here.
Loading…